Who performs clinical trial results disclosure, and when

Trial transparency has become one of the few areas of regulated activity where failure is visible from outside the organisation. Registration records and results summaries are public, their due dates are derived from public milestones, and anyone can check. That visibility has not been matched by clarity in the agreements that decide who actually does the work.

The regimes themselves are reasonably clear. In the United States, registration and results submission duties for applicable clinical trials sit with the responsible party under the framework established by the Food and Drug Administration Amendments Act and its implementing rule. In the European Union, the Clinical Trials Regulation requires sponsors to submit summary results into the Clinical Trials Information System within defined periods after trial end. Other jurisdictions impose their own registration and reporting requirements.

What is rarely clear is the contractual layer underneath. Sponsor, CRO and site agreements frequently describe transparency in a single sentence, or not at all, which leaves the operational steps unowned. This article is about allocating those steps so the public deadline is met by design rather than by somebody noticing in time.

The five operational steps that need an owner

Disclosure is not one task. It is a short sequence of tasks with different skills and different timelines, and the common failure is treating it as a single line item in a scope of work.

• Preparing the registration record, assembling study identifiers, design information, eligibility criteria and outcome measures into the registry format before the applicable trigger date.
• Keeping the record current, updating recruitment status, site information and completion dates through the life of the study, which is a recurring duty rather than a one-off filing.
• Drafting the results summary, producing the results and, where required, the lay summary, in the format and language the relevant registry demands.
• Review and authorisation, sponsor medical, regulatory and legal review inside a defined window, with a recorded approval that authorises submission.
• Submission and confirmation, performing the filing, capturing the confirmation and retaining the version posted as evidence against the governing clause.

Written out like that, the allocation question answers itself: the drafting and mechanics can sit with a CRO, the review and authorisation cannot, and the evidence has to come back to the sponsor regardless of who pressed the button. What the agreement needs to do is say so.

Where the agreements commonly fall short

Five gaps recur across sponsor, CRO and site paper. None of them are controversial once identified, which is what makes them worth a template pass rather than case-by-case negotiation.

• Transparency named but not scoped. The scope of work says the CRO will support transparency activities without naming deliverables or dates, so nothing is actually owed on any particular day
• Open-ended sponsor review rights. A publication clause with no cap on sponsor review can conflict with a fixed disclosure deadline, and the clause rarely says which one yields
• Site data delivery left vague. The sponsor needs site-level information to complete a filing, but the site agreement does not say what, in what format, or by when
• No confirmation deliverable. Submission happens and nobody owes the sponsor proof of it, so the evidence exists only in a registry account the sponsor may not control
• Milestone-blind deadlines. Dates are written as fixed calendar entries rather than derived from trial completion, so they become wrong the first time a timeline shifts

A five-step roadmap for getting transparency into the contract layer

Step 1, map the applicable regimes per study

Jurisdiction, trial type and product status determine which registration and results obligations apply, and many studies sit under more than one regime with different triggers and periods. Record the applicable regimes as study attributes rather than leaving them in a regulatory affairs memo.

Step 2, write the deliverables into the scope of work

Replace general transparency language with named deliverables, each with an owner and a date derived from a study milestone. A short table in the scope of work does more useful work here than a paragraph of intent, and it gives both parties something to manage against.

Step 3, cap the review window in the publication clause

Set a defined sponsor review period, allow a single limited extension for intellectual property reasons, and state that the clause does not override mandatory disclosure. This resolves the conflict in advance rather than during the week the deadline falls.

Step 4, derive obligation dates from milestones

Hold primary completion and trial end as fields, and generate the obligation due dates from them with the buffer applied. When the timeline moves, the obligations move with it, which is the only version of this that survives a real study.

Step 5, report on the pipeline, not the breaches

Publish a forward view of registrations and results filings due in the next two quarters, with owner, status and buffer remaining. A backward-looking compliance report tells you what already went wrong; the forward view is what prevents it.

Why this lands on contract teams

Regulatory affairs usually knows the rules precisely. What regulatory affairs does not control is the service agreement that determines whether a CRO owes a results summary on a date, or the site agreement that determines whether a site must hand over a dataset. Those are contract terms, and the organisations that meet transparency deadlines reliably are the ones where the contract layer carries the same precision as the regulatory interpretation. The mechanism is the same one used for any other regulated commitment: a named duty, a dated trigger, a role owner and a retained artefact. Sponsors already running CRO master service agreements with tracked change control have the harder half of this built.

Allocating the steps across the three agreements

The table shows a workable default allocation. Adjust it to the operating model, but keep the principle: drafting and mechanics are delegable, authorisation is not, and the evidence always returns to the sponsor.

Transparency obligations are unusually easy to manage and unusually unforgiving when they are not. The deadlines are derivable, the deliverables are definable, and the work is routine. What makes them fail is a contract layer that describes the outcome without allocating the steps, combined with calendar dates that stop being correct the first time a study timeline moves. Fixing both is a template exercise and a configuration exercise, and neither one requires a change in how the science is done. Teams tracking regulatory commitments through obligation management for life sciences already have the register these duties belong in.

For related guidance, see The quality leader’s guide to pharma quality agreements, Quality agreement obligations pharma teams keep missing and What a GLP testing facility agreement must carry.

Aavenir Life Sciences & Pharma PracticePractitioners working on clinical trial agreements, transparency commitments and obligation tracking across Aavenir deployments.